Fluvoxamine and fluoxetine in the treatment of patients with the novel coronavirus infection

Abstract

Depression is the most common mental illness in the world, affecting 4.4 % of the world's population. There is a large number of depression types, each of which is characterized by signs atypical for other types: a seasonal pattern, increased anxiety, psychotic features, melancholy, and many others. Each type of depression may respond to certain types of pharmacological treatment better than others, but despite a variety of treatment methods, depressive disorders remain difficult to treat due to many factors, including the relatively high relapse rate during treatment and the adverse side effects of the drugs used. This article discusses the use of SSRIs fluoxetine and fluvoxamine in the treatment of depressive disorders and their impact on the COVID-19 course.